Get the app
USHealthcare

The Cooper Companies, Inc (COO)

US · Healthcare · Medical Instruments & Supplies

$53.77-1.53%
Last close · 2026-09-17

Latest quarter · ended 2026-07-31

Revenue
$1.07B
Revenue YoY
+0.6%
Net profit
$432.8M
Profit YoY
+340.3%
EPS
$1.15
EPS estimate
$1.11
Net margin
40.6%

EPS came in at 1.15 against a street estimate of 1.11 — a beat of 3.6%.

Key statistics

Market cap
$10.38B
P/E
18.3
Forward P/E
10.9
P/B
1.22
Book value
$43.81
EPS (TTM)
$2.98
52-week high
$89.83
52-week low
$51.01
50-day MA
$70.58
200-day MA
$72.77
Beta
0.82

Analyst view

Analysts rate The Cooper Companies, Inc a buy (11 buy, 8 hold, 0 sell out of 19) with an average price target of $66.21.

From the latest earnings call · 2026-09-09

MIXED Cooper beat Q3 earnings and posted record free cash flow, but proactively destocked U.S. channel inventory, cutting CooperVision growth guidance from ~4% to flat for fiscal 2H. Strategic review concluded with no CooperSurgical sale. Underlying demand remains mid-single-digit. Q3 FY26 CooperVision facing temporary regional headwinds; EMEA performing well; Asia Pac stabilizing after rationalization efforts. Analysts pressed hard on destock magnitude, timing, and why not extend to other regions. Management clarified it's entirely inventory (not fundamentals), quantified ~5% revenue drag in Americas if not for destocking, and ring-fenced Q4 as final phase. Differentiated EMEA's subscription model as naturally resistant to swings. 2026-09-09…

Full summary in the app.

Shareholding

Insiders
0.63%
Institutions
111.90%

Largest institutional holders

FundStake
BlackRock Inc8.74%
Vanguard Capital Management, LLC6.69%
T. Rowe Price Investment Management,Inc.4.77%
State Street Corp4.61%
Vanguard Portfolio Management, LLC4.59%
Browning West LP3.79%
Kayne Anderson Rudnick Investment Management LLC3.48%
T. Rowe Price Associates, Inc.2.84%

Recent filings & reports

DocumentDate
Quarterly report · Q3 FY2026
THE COOPER COMPANIES, INC. - Q3 2026 10-Q SUMMARY HEADLINE NUMBERS • Net sales (9 months): $3,171.8 million vs. $3,027.3 million prior year (+4.8%)
2026-09-09
Results announced · Q4 FY2026
COOPER COMPANIES Q3 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Q3 2026 revenue: $1.066 billion, up 1% year-over-year on organic basis • GAAP diluted
2026-09-09
Quarterly report · Q2 FY2026
COOPER COMPANIES, INC. – Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Q2 2026 Net Sales: $1,081.5 million (vs. $1,002.3 million Q2 2025, +7.9%) • Six-Mon
2026-06-05
Results announced · Q3 FY2026
COOPERCOMPANIES Q2 2026 RESULTS SUMMARY HEADLINE NUMBERS • Revenue: $1.082 billion in Q2 2026, up 8% reported (5% organic growth) • GAAP diluted EPS
2026-06-04
Board / officer change · Q3 FY2026
THE COOPER COMPANIES, INC. - FORM 8-K SUMMARY BUSINESS & SEGMENT HIGHLIGHTS • The Cooper Companies announced the expansion of its Board of Directors
2026-05-04
Shareholder vote results · Q2 FY2026
THE COOPER COMPANIES, INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • Annual Meeting of Stockholders held April 7, 2026 • Total votes cast: approximately
2026-04-08
Quarterly report · Q1 FY2026
THE COOPER COMPANIES, INC. – Q1 FY2026 (Ended January 31, 2026) – SUMMARY FOR RETAIL INVESTORS --- HEADLINE NUMBERS • Net Sales: $1,024.1 million (
2026-03-06
Results announced · Q2 FY2026
COOPER COMPANIES Q1 2026 RESULTS SUMMARY HEADLINE NUMBERS • Total revenue: $1.024 billion, up 6% reported / up 3% organically year-over-year • GAAP
2026-03-05

Readable in the app.

Corporate actions

ActionDetailDate
Split4 : 1
effective Feb 20, 2024
2024-02-20

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for The Cooper Companies, Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Data updated 2026-09-18.